Source: International Congress 2017 – Management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kostikas (Basel, Switzerland). Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial. 3253

Member's Comments

No comment yet.

Related content which might interest you: Change in clinical COPD questionnaire (CCQ) symptoms domain score and FEV1 predict treatment failure during hospitalisation due to COPD exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Determining SGRQ and TDI responder rates across the duration of clinical trials: Results from tiotropium + olodaterol in COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Value of measuring SGRQ at stable phase of COPD to predict the timing and deterioration associated with next exacerbation: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 240s Year: 2004 Correlation of airway obstruction and patient-reported endpoints in clinical studies Source: Eur Respir J 2001; 17: 220-224 Year: 2001 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Clinically meaningful FEV1 response with reslizumab achieved early and sustained over 52 weeks Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 Short-term recovery in SGRQ following a COPD exacerbation in the MOSAIC study correlates with the preceding deterioration, but is larger Source: Eur Respir J 2004; 24: Suppl. 48, 686s Year: 2004 Duration and frequency of spirometry needed to accurately reflect longitudinal change of FEV1 in COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001 Longitudinal modeling of prebronchodilator FEV1 response to benralizumab for patients with severe asthma Source: International Congress 2017 – Asthma management Year: 2017 Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study Source: International Congress 2018 – COPD management Year: 2018 Basal FEV1 does not predict the long term response to salmeterol/fluticasone in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016